Cibus Global LLC (CBUS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Cibus Global LLC stock (CBUS) is currently trading at $2.71. Cibus Global LLC PS ratio (Price-to-Sales) is 48.23. Analyst consensus price target for CBUS is $14.30. WallStSmart rates CBUS as Sell.
- CBUS PE ratio analysis and historical PE chart
- CBUS PS ratio (Price-to-Sales) history and trend
- CBUS intrinsic value — DCF, Graham Number, EPV models
- CBUS stock price prediction 2025 2026 2027 2028 2029 2030
- CBUS fair value vs current price
- CBUS insider transactions and insider buying
- Is CBUS undervalued or overvalued?
- Cibus Global LLC financial analysis — revenue, earnings, cash flow
- CBUS Piotroski F-Score and Altman Z-Score
- CBUS analyst price target and Smart Rating
Cibus Global LLC
📊 No data available
Try selecting a different time range
Smart Analysis
Cibus Global LLC (CBUS) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Cibus Global LLC (CBUS) Key Strengths (0)
Supporting Valuation Data
Cibus Global LLC (CBUS) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -12.80%, a shrinking business
Very expensive at 48.2x annual revenue
Very expensive at 8.0x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Cibus Global LLC (CBUS) Detailed Analysis Report
Overall Assessment
This company scores 10/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 0 register as strengths (avg 0/10) while 7 fall into concern territory (avg 1.6/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (48.23), Price/Book (7.96) suggest expensive pricing. Growth concerns include Revenue Growth at -12.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -221.00%, Operating Margin at -1273.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -221.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -12.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CBUS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CBUS's Price-to-Sales ratio of 48.23x trades at a deep discount to its historical average of 1246.41x (30th percentile). The current valuation is 99% below its historical high of 8261.43x set in Dec 2023, and 139% above its historical low of 20.14x in Sep 2025. Over the past 12 months, the PS ratio has expanded from ~30.7x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Cibus Global LLC (CBUS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Cibus Global LLC operates as a stable business with moderate growth and solid fundamentals. Revenue reached 4M with 13% decline year-over-year.
Key Findings
Spending 258% of revenue (9M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 13% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -14M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.75, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Cibus Global LLC.
Bottom Line
Cibus Global LLC offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:02:10 AM
About Cibus Global LLC(CBUS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Cibus Global, Ltd., a biotechnology company, develops plant traits for seed industry globally. The company is headquartered in San Diego, California.